Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicentre, single-arm, phase II trial
Phase II trial shows serplulimab combined with gemcitabine and nab-paclitaxel improves progression-free survival in mPDAC patients, indicating promising efficacy.
Key Points
The combination treatment achieved a 78.7% progression-free survival rate at six months in patients with mPDAC.
Among 47 patients, the objective response rate was noted at 74.5%, showcasing significant antitumour activity.
This phase II trial assessed the efficacy of serplulimab with chemotherapy and radiation therapy across multiple centers.
Findings suggest the need for further validation through a phase III randomized trial to confirm these promising results.